Development of a novel safe and efficacious biologic drug for the treatment of AML
Ended Project Grant Awarded Last action
- Award ID
- R41CA235796
- Recipient
-
Enzyme By Design Inc. UEI CKUTZNUHGRN7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,552
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Illinois, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $299,552 |
Quick answers
Who received award R41CA235796?
R41CA235796 was awarded to Enzyme By Design Inc. by National Cancer Institute (National Institutes of Health) on September 20, 2018.
How much is award R41CA235796 worth?
$299,552 has been obligated on R41CA235796.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award